Skip to main content

Triamcinolone Acetonide

FDA recalls

5 rows

DateCompany and reasonClass
Sep 27, 2023Eugia US LLC
Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial.
Class II · Ongoing
Aug 16, 2022Padagis US LLC
CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.
Class II · Terminated
Apr 12, 2022McKesson Medical-Surgical Inc. Corporate Office
cGMP deviations: Temperature abuse
Class II · Terminated
Mar 14, 2021Cardinal Health Inc.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II · Terminated
Jan 28, 2014Fougera Pharmaceuticals Inc.
Labeling: Label Error on Declared Strength: There is a misprint on the end flap which read 01% rather than 0.1%.
Class III · Terminated

← Back to Triamcinolone Acetonide

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).